Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

On December 3, Guggenheim raised its price target on Eli Lilly and Company (NYSE:LLY) to $1,163 from $1,036 and kept a Buy ...

Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

Together, these stocks offer you a balanced mix of growth and safety. These companies span a number of industries, and many ...

But my prediction is one of the next members of this club won't be a tech player: Instead, a surprising growth stock will ...

For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...

In a significant move to address supply constraints, Eli Lilly announced a $6 billion investment to construct a new manufacturing facility in Huntsville, Alabama. This site is slated to produce both ...